UNASSIGNED: The aim of this study was to summarize published data on the effectiveness, adverse effects, and acceptability of the various combinations of mifepristone and misoprostol in medical abortion protocols in the first trimester of pregnancy.
UNASSIGNED: This was a comprehensive review, synthesizing the findings of the literature on the current use of mifepristone and misoprostol for first-trimester abortion.
UNASSIGNED: The combination of mifepristone and misoprostol seems to be more effective than misoprostol alone. Regarding the dosages and routes, mifepristone is administered orally, and the optimal dose is 200 mg. The route of administration of misoprostol varies; the sublingual and buccal routes are more effective; however, the vaginal route (800 μg) is associated with fewer adverse effects. Finally, the acceptability rates did not differ significantly.
UNASSIGNED: Different schemes for first-trimester medical abortion have been described so far. Future research needs to focus on identifying the method that offers the best trade-off between efficacy and safety in first-trimester medical abortion.
■这项研究的目的是总结已发表的有效性数据,不利影响,以及米非司酮和米索前列醇的各种组合在妊娠早期药物流产方案中的可接受性。
■这是一个全面的审查,综合目前使用米非司酮和米索前列醇进行妊娠早期流产的文献发现。
■米非司酮和米索前列醇的组合似乎比单独使用米索前列醇更有效。关于剂量和路线,米非司酮口服给药,最佳剂量为200毫克。米索前列醇的给药途径各不相同;舌下和口腔途径更有效;然而,阴道途径(800μg)不良反应较少。最后,可接受率没有显著差异.
■到目前为止,已经描述了妊娠早期药物流产的不同方案。未来的研究需要集中在确定在妊娠早期药物流产中在疗效和安全性之间提供最佳权衡的方法上。